However, tentative evidence that, on average, high ERCC1 expression identifies poorer survival in NSCLC patients treated with platinum-based chemotherapy, provided indirect evidence of a predictive influence, although this may be merely a prognostic effect in this patient group. The gene discussed is ERCC1; the disease is non-small cell lung carcinoma.